Please ensure Javascript is enabled for purposes of website accessibility

Why CureVac Stock Is Getting Crushed Today

By George Budwell - Jun 17, 2021 at 11:06AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's COVID-19 vaccine candidate no longer appears to be viable.

What happened

Shares of German biotech CureVac (CVAC -5.39%) are down by a hefty 49.9% as of 9:47 a.m. EDT Thursday morning. The biotech's shares are getting walloped today in response to disappointing late-stage trial results for its COVID-19 vaccine candidate known as CVnCoV.

Specifically, CureVac reported that the experimental vaccine completely whiffed on its second interim analysis. Despite being a messenger RNA (mRNA) vaccine, which is the same platform used to develop the Pfizer/BioNTech and Moderna vaccines, this early peek revealed that CVnCoV was less than half as effective (47%) as its predecessors at preventing COVID-19 infections. 

A doctor taking care of a COVID-19 patient.

Image source: Getty Images.

So what

CureVac blamed the vaccine's poor efficacy -- compared to other mRNA vaccines already on the market -- on the large number of COVID-19 variants currently in circulation. The first round of mRNA vaccines were trialed before most of these variants became widespread.

While the vaunted U.S. market is arguably already saturated with COVID-19 vaccines, CureVac stood a decent shot at carving out a profitable niche with its vaccine in several ex-U.S. territories. Following these underwhelming trial results, however, the biotech probably won't realize a significant financial benefit from this once-promising product candidate. 

Now what

Can CureVac stock bounce back soon? Wall Street was expecting a lot from this vaccine from a revenue generation standpoint, to put it mildly.

The biotech, in fact, may have just lost upward of $3 billion in future revenue. In other words, CureVac's shares are unlikely to rally anytime soon. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CureVac N.V. Stock Quote
CureVac N.V.
CVAC
$12.47 (-5.39%) $0.71
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$48.48 (-1.61%) $0.80
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$150.43 (-4.79%) $-7.57
BioNTech SE Stock Quote
BioNTech SE
BNTX
$148.40 (-2.39%) $-3.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.